Prescient said the acquisition will expand its lab capabilities and enhance its relationships with local, regional, and national health insurers.
The test analyzes clinically relevant genetic variants for 14 genes related to certain pain and mental health medication responses to help guide clinicians' prescribing decisions.
RPRD will expand the availability of its PGx testing services to South Korea, and Orient Bio will diversify its business to include precision medicine and clinical PGx.
The two firms will offer their technologies and services to patients in Hong Kong, Japan, and Macau to improve drug dosing and prescriptions.
The deals will expand the availability of Admera's pharmacogenomics testing services to markets including Singapore, Hong Kong, Korea, and Taiwan.
The RightMed test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.
The test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.
The two firms are offering a combined genetic disease risk and pharmacogenomic analysis that covers 49 conditions and about 220 medications.
The companies will develop a smartphone-based platform to offer molecular tests enabling the precision treatment of psychiatric disorders.
The group, made up of three Rennova subsidiaries, will focus on mental and behavioral health, oncology, urology, and cardiovascular disease.